跳至主要内容
临床试验/NCT01267357
NCT01267357已完成不适用

Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2010年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
62
试验地点
1
主要终点
Overall survival

研究概览

简要总结

P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value.

The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.

following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.

Blocks from endometrioid endometrial cancer will be used as a control group.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • diagnosis of endometrial cancer
  • histology block exists in hospital's library

排除标准

  • 未提供

结局指标

主要结局

Overall survival

时间窗: last followup (2-10 years)

次要结局

  • progression free survival(Current follow up (2-10 years))
  • correlation of P16 stain with histological diagnosis(at last follow up (2-10 years))

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验